Quotables
"Fooling around with alternating current is just a waste of time. Nobody will use it, ever."
Thomas Edison ; 1889
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8124768 | 4-pyridinone compounds and their use for cancer Disclosed are compounds of Formula (I): and salts thereof. Also, disclosed are methods of using the compounds in the treatment of proliferative diseases, such as cancer, and to pharmaceutical compositions comprising at leas... | 02/28/2012 |
| 7358361 | Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases Bisphosphonate compounds and related methods of making and using are disclosed, including pyridinium-1-yl, quinolinium-1-yl, and related compounds. The activity of compounds is disclosed in the context of functional assays such as Leishmania major farnesyl di... | 04/15/2008 |
| 7320993 | Aryl-substituted pyridylalkane, alkene, and alkine carboxamides useful as cytostatic useful as cytostatic and immuosuppressive agents The invention relates to new pyridylalkane, alkene, and alkine acid amides substituted with an aryl and/or heteroaryl residue according to the general formula (I), with a saturated or one or several-fold unsaturated hydrocarbon residue in the carboxylic acid group, ... | 01/22/2008 |
| 7312326 | Fluorescent labeled nucleotide derivatives Fluorescent labeled reporter compounds having a modified cyanine dye that is coupled to a nucleotide derivative through a linker are disclosed. The compounds are useful for nucleic acid sequence analysis. The fluorescent labeled reporter compounds are ring-locked cy... | 12/25/2007 |
| 7256152 | Composition of catalyst and solvent and catalysis processes using this composition A composition defined: either as comprising at least one Broensted acid, designated HB, dissolved in a liquid medium with an ionic nature of general formula Q+A−, in which Q+ represents an organic cation and A− represents an an... | 08/14/2007 |
| 7250470 | Crystallization of polypropylene using a semi-crystalline, branched or coupled nucleating agent A method of nucleating a propylene homo- or copolymer, the method comprising contacting the propylene polymer with a semi-crystalline branched or coupled polymeric nucleating agent under nucleation conditions. In one embodiment, the propylene homopolymer is characte... | 07/31/2007 |
| 7250471 | Impact resistance polymer blends of crystalline polypropylene and partially crystalline, low molecular weight impact modifiers Polymer blends that exhibit good impact resistance comprise a crystalline polypropylene matrix and a partly crystalline copolymer impact modifier with a molecular weight lower than that of the matrix polymer. The matrix polymer can comprise any crystalline propylene... | 07/31/2007 |
| 7208481 | Aminodiphosphonate apolipoprotein E modulators The present invention relates to methods of use of aminodiphosphonate to modulate apolipoprotein E levels and the use of such compounds in therapy, including cardiovascular and neurological disease states. ... | 04/24/2007 |
| 7199203 | Isotactic propylene copolymer fibers, their preparation and use Fibers comprising a propylene homopolymer or a copolymer of propylene and at least one of ethylene and one or more unsaturated comonomers exhibit desirable properties. The homopolymers are characterized as having 13C NMR peaks corresponding to a regio-err... | 04/03/2007 |
| 7160513 | Batch reactor with injection system An apparatus and method for injection of one or more chemical components into a reaction chamber are disclosed. The apparatus includes a reaction chamber for receiving one or more libraries in a fixed position relative to the chamber and configured to form a sealed ... | 01/09/2007 |
| 7129228 | Heterocyclic analgesic compounds and methods of use thereof One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-couple... | 10/31/2006 |
| 7119232 | Nucleophilic substitution reactions of difluorormethyl phenyl sulfone with alkyl halides leading to the facile synthesis of terminal 1,1-difluoro-1-alkenes and difluoromethylalkanes (Benzenesulfonyl)difluoromethyl anion, in situ generated from difluoromethyl phenyl sulfone and a base, was found to easily undergo nucleophilic substitution reactions (SN2) with primary alkyl halides, elemental halogens, and perfluoroalkyl halides with g... | 10/10/2006 |
| 7109269 | Impact resistant polymer blends of crystalline polypropylene and partially crystalline, low molecular weight impact modifiers Polymer blends that exhibit good impact resistance comprise a crystalline polypropylene matrix and a partly crystalline copolymer impact modifier with a molecular weight lower than that of the matrix polymer. The matrix polymer can comprise any crystalline propylene... | 09/19/2006 |
| 7105556 | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method Compounds are provided which have the structure wherein Q is C or N, X1 is C or N, and R1, R2, R2a, R2b, R2c, R3, Y, A, m, n, X2 | 09/12/2006 |
| 7060754 | Crystallization of polypropylene using a semi-crystalline, branched or coupled nucleating agent A method of nucleating a propylene homo- or copolymer, the method comprising contacting the propylene polymer with a semi-crystalline branched or coupled polymeric nucleating agent under nucleation conditions. In one embodiment, the propylene homopolymer is characte... | 06/13/2006 |
| 7041765 | Films comprising isotactic propylene copolymers Films with excellent machine direction (MD) tear properties comprise at least one layer made from a polymer comprising: (A) at least 50 weight percent (wt%) propylene; and (B) at least 5 wt % ethylene and/or one or more unsaturated comonomers. Represen... | 05/09/2006 |
| 7030103 | Sulfonamidomethyl phosphonate inhibitors of β-lactamase The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel β-lactamase inhibitors, which are structurally unrelated to the natural product and... | 04/18/2006 |
| 6977260 | Piperidinyl prostaglandin E analogs The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; | 12/20/2005 |
| 6960635 | Isotactic propylene copolymers, their preparation and use Unique copolymers comprising propylene, ethylene and/or one or more unsaturated comonomers are characterized as having: at least one, preferably more than one, of the following properties: (i) 13C NMR peaks corresponding to a regio-error at about 14.6 and... | 11/01/2005 |
| 6946535 | Films comprising isotactic propylene copolymers Films with excellent machine direction (MD) tear properties comprise at least one layer made from a polymer comprising: (A) at least 50 weight percent (wt %) propylene; and (B) at least 5 wt % ethylene and/or one o... | 09/20/2005 |
| 6943215 | Impact resistant polymer blends of crystalline polypropylene and partially crystalline, low molecular weight impact modifiers Polymer blends that exhibit good impact resistance comprise a crystalline polypropylene matrix and a partly crystalline copolymer impact modifier with a molecular weight lower than that of the matrix polymer. The matrix polymer can comprise any crystalline propylene... | 09/13/2005 |
| 6927256 | Crystallization of polypropylene using a semi-crystalline, branched or coupled nucleating agent A method of nucleating a propylene homo- or copolymer, the method comprising contacting the propylene polymer with a semi-crystalline branched or coupled polymeric nucleating agent under nucleation conditions. In one embodiment, the propylene homopolymer is characte... | 08/09/2005 |
| 6927258 | Elastic blends comprising crystalline polymer and crystallizable polymers of propylene Improved thermoplastic polymer blend compositions comprising an isotactic polypropylene component and an alpha-olefin and propylene copolymer component, said copolymer comprising crystallizable alpha-olefin sequences. In a preferred embodiment, improved thermoplasti... | 08/09/2005 |
| 6921756 | Inhibitors of β-lactamase The invention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel β-lactamase inhibitors, which are structurally unrelated to the natural product and... | 07/26/2005 |
| 6919407 | Blends and sealant compositions comprising isotactic propylene copolymers Films with excellent machine direction (MD) tear properties comprise at least one layer made from a polymer comprising: (A) at least 50 weight percent (wt %) propylene; and (B) at least 5 wt % ethylene and/or one o... | 07/19/2005 |
| 6911410 | Catalyst composition containing an aluminoxane for dimerizing, co-dimerizing and oligomerizing olefins A catalyst composition for use in dimerizing, co-dimerizing or oligomerizing olefins results from dissolving a nickel compound, optionally mixed or complexed with a ligand, in a medium resulting from mixing: at least one quaternary... | 06/28/2005 |
| 6906160 | Isotactic propylene copolymer fibers, their preparation and use Fibers comprising a propylene homopolymer or a copolymer of propylene and at least one of ethylene and one or more unsaturated comonomers exhibit desirable properties. The homopolymers are characterized as having 13C NMR peaks corresponding to a regio-err... | 06/14/2005 |
| 6896871 | Biphosphonate conjugates and methods of making and using the same The present invention is directed to particular bisphosphonate compounds, and in particular, to bisphosphonate conjugates that are useful in the treatment of soft tissues surrounding bone and bone-related diseases, such as bone cancer and osteoporosis. ... | 05/24/2005 |
| 6884791 | Inhibitors of β-lactamase The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel β-lactamase inhibitors, which are structurally unrelated to the natural product and... | 04/26/2005 |
| 6872711 | β-substituted β-aminoethyl phosphonate derivatives The present invention relates to novel β-substituted-β-aminoethylphosphonate derivatives and their uses for lowering plasma levels of apo (a), Lp(a), apo B, apo B associated lipoproteins (low density lipoproteins and very low density lipoproteins) and for lowering... | 03/29/2005 |
| 6750340 | Bisphosphonate conjugates and methods of making and using the same The present invention is directed to particular bisphosphonate compounds, and in particular, to bisphosphonate conjugates that are useful in the treatment of soft tissues surrounding bone and bone-related diseases, such as bone cancer and osteoporosis. ... | 06/15/2004 |
| 6747037 | Piperidinyl prostaglandin E analogs The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; | 06/08/2004 |
| 6727361 | Phosphino substituted pyridine amine ligands New ligands, compositions, metal-ligand complexes and arrays with pyridyl-amine ligands are disclosed that catalyze the polymerization of monomers into polymers. Certain of these catalysts with hafnium metal centers have high performance characteristics, including h... | 04/27/2004 |
| 6723711 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors A compound of the structure A method for the inhibition of the binding of α4β1 integrin to its receptors, for example VCAM-1(vascular cell adhesion molecule-1) and fibronectin; pharmaceutically ac... | 04/20/2004 |
| 6703507 | Ionic liquids and production and use thereof The invention relates to novel ionic liquids and to the production and use thereof. The novel ionic liquids are salts of sulphonated or carboxylated triesters of phosphorous acid as the anionic component and ammonium ions, which can be substituted with or... | 03/09/2004 |
| 6667315 | Cardioprotective phosphonates and malonates The present invention provides for pyridoxine phosphonate analogues such as, for example, ((2-methyl-3-hydroxy-4-hydroxymethyl-5-pyridyl)alkylphosphonates, and (2-methyl-3-hydroxy-4-hydroxymethyl-5-pyridyl)azaalkylphosphonates) and to pyridoxine malo... | 12/23/2003 |
| 6660860 | Process for the selective oxidation of alcohols using readily removable nitroxyl radicals The invention relates to a process for the selective oxidation of alcohols to ketones or to aldehydes by means of an alkali hypohalite under alkaline conditions, which comprises carrying out the oxidation in the presence of a heterogeneous oxidation catal... | 12/09/2003 |
| 6653296 | Antiretroviral enantiomeric nucleotide analogs Resolved enantiomers of the formula (IA) and (IB) ##STR1## wherein B is a purine or pyrimidine base or aza and/or deaza analogs thereof are useful in antiviral pharmaceutical compositions to treat retroviral infections.... | 11/25/2003 |
| 6576760 | Processes for synthesis of cyclic and linear polyamine chelators containing N-monosubstituted coordinating arms Polyamines containing at least two nitrogen atoms monosubstituted with pendant arms capable of coordinating metal cations, or with precursors of such pendant arms, all nitrogen atoms of the polyamines except two being fully substituted and the remaining t... | 06/10/2003 |
| 6509359 | Pyrrolidin-2-one compounds and their use as neuraminidase inhibitors A compound having the formula: ##STR1## wherein all variables are as defined in the specification, for use as a neuramninidase inhibitor.... | 01/21/2003 |
